Date: 2013-07-26
Type of information: Licensing agreement
Compound:
Company: GSK (UK) Adimab (USA - NH)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On July 26, 2013, Adimab, a company dedicated to the discovery of fully human monoclonal and bispecific antibodies, has announced its first platform technology transfer and license agreement with GSK. Adimab will receive significant upfront payments, annual licensing fees, and royalties on resulting commercialized products. Under the agreement, GSK has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of all antibody formats, including bispecific antibodies.
Under the terms of the agreement, GSK will have a broad license to the Adimab antibody discovery platform and a unique custom antibody library that is exclusive to GSK. In addition, GSK has secured an option to receive continued access to improvements to the Adimab antibody discovery platform, including access to subsequently-developed libraries. Adimab will receive a series of payments, including a significant upfront cash payment, annual license fees and research and development milestones. Adimab will also receive royalties and commercial milestones on a defined number of therapeutic products.
Financial terms:
Latest news:
